Adnexal Masses: Benign Ovarian Lesions and Characterization
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Imaging in Gynecology: What Is Appropriate Francisco A
Imaging in Gynecology: What is Appropriate Francisco A. Quiroz, MD Appropriate • Right or suitable • To set apart for a specific use Appropriateness • The quality or state for being especially suitable or fitting 1 Imaging Modalities Ultrasound Pelvis • Trans abdominal • Transvaginal Doppler 3-D • Hysterosonogram Computed Tomography MR PET Practice Guidelines Describe recommended conduct in specific areas of clinical practice. They are based on analysis of current literature, expert opinion, open forum commentary and informal consensus Consensus Conference National Institutes of Health (NIH) U.S. Preventive Services Task Force Centers for Disease Control (CDC) National Comprehensive Cancer Network (NCCN) American College of Physicians American College of Radiology Specialty Societies 2 Methodology Steps in consensus development ? • Formulation of the question or topic selection • Panel composition – requirements • Literature review • Assessment of scientific evidence or critical appraisal • Presentation and discussion • Drafting of document • Recommendations for future research • Peer review • Statement document • Publication – Dissemination • Periodic review and updating ACR Appropriateness Criteria Evidence based guidance to assist referring physicians and other providers in making the most appropriate imaging or treatment decision for a specific clinical condition 3 Appropriateness Criteria Expert panels • Diagnostic imaging • Medical specialty organizations American Congress of Obstetricians and Gynecologists -
Germline Fumarate Hydratase Mutations in Patients with Ovarian Mucinous Cystadenoma
European Journal of Human Genetics (2006) 14, 880–883 & 2006 Nature Publishing Group All rights reserved 1018-4813/06 $30.00 www.nature.com/ejhg SHORT REPORT Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma Sanna K Ylisaukko-oja1, Cezary Cybulski2, Rainer Lehtonen1, Maija Kiuru1, Joanna Matyjasik2, Anna Szyman˜ska2, Jolanta Szyman˜ska-Pasternak2, Lars Dyrskjot3, Ralf Butzow4, Torben F Orntoft3, Virpi Launonen1, Jan Lubin˜ski2 and Lauri A Aaltonen*,1 1Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland; 2International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland; 3Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, Denmark; 4Pathology and Obstetrics and Gynecology, University of Helsinki, Helsinki, Finland Germline mutations in the fumarate hydratase (FH) gene were recently shown to predispose to the dominantly inherited syndrome, hereditary leiomyomatosis and renal cell cancer (HLRCC). HLRCC is characterized by benign leiomyomas of the skin and the uterus, renal cell carcinoma, and uterine leiomyosarcoma. The aim of this study was to identify new families with FH mutations, and to further examine the tumor spectrum associated with FH mutations. FH germline mutations were screened from 89 patients with RCC, skin leiomyomas or ovarian tumors. Subsequently, 13 ovarian and 48 bladder carcinomas were analyzed for somatic FH mutations. Two patients diagnosed with ovarian mucinous cystadenoma (two out of 33, 6%) were found to be FH germline mutation carriers. One of the changes was a novel mutation (Ala231Thr) and the other one (435insAAA) was previously described in FH deficiency families. These results suggest that benign ovarian tumors may be associated with HLRCC. -
American Family Physician Web Site At
Diagnosis and Management of Adnexal Masses VANESSA GIVENS, MD; GREGG MITCHELL, MD; CAROLYN HARRAWAY-SMITH, MD; AVINASH REDDY, MD; and DAVID L. MANESS, DO, MSS, University of Tennessee Health Science Center College of Medicine, Memphis, Tennessee Adnexal masses represent a spectrum of conditions from gynecologic and nongynecologic sources. They may be benign or malignant. The initial detection and evaluation of an adnexal mass requires a high index of suspicion, a thorough history and physical examination, and careful attention to subtle historical clues. Timely, appropriate labo- ratory and radiographic studies are required. The most common symptoms reported by women with ovarian cancer are pelvic or abdominal pain; increased abdominal size; bloating; urinary urgency, frequency, or incontinence; early satiety; difficulty eating; and weight loss. These vague symptoms are present for months in up to 93 percent of patients with ovarian cancer. Any of these symptoms occurring daily for more than two weeks, or with failure to respond to appropriate therapy warrant further evaluation. Transvaginal ultrasonography remains the standard for evaluation of adnexal masses. Findings suggestive of malignancy in an adnexal mass include a solid component, thick septations (greater than 2 to 3 mm), bilaterality, Doppler flow to the solid component of the mass, and presence of ascites. Fam- ily physicians can manage many nonmalignant adnexal masses; however, prepubescent girls and postmenopausal women with an adnexal mass should be referred to a gynecologist or gynecologic oncologist for further treatment. All women, regardless of menopausal status, should be referred if they have evidence of metastatic disease, ascites, a complex mass, an adnexal mass greater than 10 cm, or any mass that persists longer than 12 weeks. -
Pseudocarcinomatous Hyperplasia of the Fallopian Tube Mimicking Tubal
Lee et al. Journal of Ovarian Research (2016) 9:79 DOI 10.1186/s13048-016-0288-x CASE REPORT Open Access Pseudocarcinomatous hyperplasia of the fallopian tube mimicking tubal cancer: a radiological and pathological diagnostic challenge Nam Kyung Lee1,2†, Kyung Un Choi3†, Ga Jin Han1, Byung Su Kwon4, Yong Jung Song4, Dong Soo Suh4 and Ki Hyung Kim2,4* Abstract Background: Pseudocarcinomatous hyperplasia of the fallopian tube is a rare, benign disease characterized by florid epithelial hyperplasia. Case presentation: The authors present the history and details of a 22-year-old woman with bilateral pelvic masses and a highly elevated serum CA-125 level (1,056 U/ml). Ultrasonography and magnetic resonance imaging (MRI) of the pelvis showed bilateral adnexal complex cystic masses with a fusiform or sausage-like shape. Contrast-enhanced fat-suppressed T1-weighted images showed enhancement of papillary projections of the right adnexal mass and enhancement of an irregular thick wall on the left adnexal mass, suggestive of tubal cancer. Based on MRI and laboratory findings, laparotomy was performed under a putative preoperative diagnosis of tubal cancer. The final pathologic diagnosis was pseudocarcinomatous hyperplasia of tubal epithelium associated with acute and chronic salpingitis in both tubes. Conclusion: The authors report a rare case of pseudocarcinomatous hyperplasia of the fallopian tubes mimicking tubal cancer. Keywords: Pseudocarcinomatous hyperplasia of the fallopian tube, Tubal cancer, Pelvic mass Background mitotic activity related to estrogenic stimulation might Various benign conditions of the female genital tract be observed in the tubal epithelium, but florid or atyp- may be confused with malignant neoplasms. -
Adnexal Masses in Pregnancy
A guide to management Mitchel S. Hoffman, MD Professor and Director, Division of Adnexal masses in pregnancy Gynecologic Oncology, Department of Obstetrics and Gynecology, Forego surgery in most cases until delivery—or until University of South Florida, Tampa, Fla Robyn A. Sayer, MD the risky fi rst trimester has passed Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, CASE 1 An enlarging cystic tumor 16 × 12 × 4 cm and determined that it University of South Florida, Tampa, Fla was a corpus luteum cyst. The authors report no fi nancial relationships relevant to this article. A 20-year-old gravida 3 para 1011 visits the emergency department with persistent right Presence of mass raises questions fl ank pain. Although ultrasonography (US) Despite the rarity of malignancy, the dis- shows a 21-week gestation, the patient has covery of an ovarian mass during pregnan- had no prenatal care. Imaging also reveals a® Dowdency prompts several Health important Media questions: right-sided ovarian tumor, 14 × 11 × 8 cm, How should the mass be assessed? How that is mainly cystic with some internal can the likelihood of malignancy be deter- echogenicity. CopyrightFor personalmined as quickly use and only effi ciently as pos- At 30 weeks’ gestation, a gynecologic sible, without jeopardy to the pregnancy? oncologist is consulted. Repeat US reveals When is surgical intervention warranted? the mass to be about 20 cm in diameter and And when can it be postponed? Specifi - cystic, without internal papillation. The pa- cally, is elective operative intervention for IN THIS ARTICLE tient’s CA-125 level is 12 U/mL. -
Non-Hodgkin's Lymphomas Involving the Uterus
Non-Hodgkin’s Lymphomas Involving the Uterus: A Clinicopathologic Analysis of 26 Cases Russell Vang, M.D., L. Jeffrey Medeiros, M.D., Chul S. Ha, M.D., Michael Deavers, M.D. Department of Pathology, The University of Texas–Houston Medical School (RV), and the Departments of Pathology (LJM, MD) and Radiation Oncology (CSH), The University of Texas–M.D. Anderson Cancer Center, Houston, Texas KEY WORDS: B-cell, Immunohistochemistry, Non- Non-Hodgkin’s lymphomas (NHL) involving the Hodgkin’s lymphoma, Uterus. uterus may be either low-stage neoplasms that Mod Pathol 2000;13(1):19–28 probably arise in the uterus (primary) or systemic neoplasms with secondary involvement. In this Non-Hodgkin’s lymphoma (NHL) can involve ex- study, 26 NHL involving the uterus are reported. tranodal sites. Common extranodal locations in- Ten cases were stage IE or IIE and are presumed to clude the gastrointestinal tract and skin; however, be primary. The mean age of patients at presenta- the female reproductive system also may be af- tion was 55 years (range, 35 to 67 years), and abnor- fected, most commonly the ovary. Infrequently, mal uterine bleeding was the most frequent com- NHL may involve the uterus. Numerous studies of plaint (six patients). Nine of 10 tumors involved the NHL involving the uterus have been reported in the cervix. Histologically, eight were diffuse large B-cell literature, and we have identified at least 15 case lymphoma (DLBCL); one was follicle center lym- series that describe three or more patients (1–16). phoma, follicular, grade 1; and one was marginal However, in most of these studies, clinical zone B-cell lymphoma. -
Rotana Alsaggaf, MS
Neoplasms and Factors Associated with Their Development in Patients Diagnosed with Myotonic Dystrophy Type I Item Type dissertation Authors Alsaggaf, Rotana Publication Date 2018 Abstract Background. Recent epidemiological studies have provided evidence that myotonic dystrophy type I (DM1) patients are at excess risk of cancer, but inconsistencies in reported cancer sites exist. The risk of benign tumors and contributing factors to tu... Keywords Cancer; Tumors; Cataract; Comorbidity; Diabetes Mellitus; Myotonic Dystrophy; Neoplasms; Thyroid Diseases Download date 07/10/2021 07:06:48 Link to Item http://hdl.handle.net/10713/7926 Rotana Alsaggaf, M.S. Pre-doctoral Fellow - Clinical Genetics Branch, Division of Cancer Epidemiology & Genetics, National Cancer Institute, NIH PhD Candidate – Department of Epidemiology & Public Health, University of Maryland, Baltimore Contact Information Business Address 9609 Medical Center Drive, 6E530 Rockville, MD 20850 Business Phone 240-276-6402 Emails [email protected] [email protected] Education University of Maryland – Baltimore, Baltimore, MD Ongoing Ph.D. Epidemiology Expected graduation: May 2018 2015 M.S. Epidemiology & Preventive Medicine Concentration: Human Genetics 2014 GradCert. Research Ethics Colorado State University, Fort Collins, CO 2009 B.S. Biological Science Minor: Biomedical Sciences 2009 Cert. Biomedical Engineering Interdisciplinary studies program Professional Experience Research Experience 2016 – present Pre-doctoral Fellow National Cancer Institute, National Institutes -
Abnormal Uterine Bleeding (AUB): an Uncommon Presentation of Ovarian Cancer
Abnormal Uterine Bleeding (AUB): an uncommon presentation of ovarian cancer Mariana López 1, Georgina Blanco 1, Jimena Lange 2, Adriana Bermudez 2, Eugenia Lamas Majek 1, Florencia García Kammermann 3, Lucía Cardinal 3, Claudia Onetto 1, Carolina Milito 1, Silvio Tatti 4, Susana Leiderman 1 1 Gynecologic Endocrinology Unit, Gynecology Division. Buenos Aires University Hospital; 2 Gynecologic Oncology Unit, Gynecology Division. Buenos Aires University Hospital; 3 Gynecologic Pathology Division, Pathology Department. Buenos Aires University Hospital; 4 Gynecology Division. Buenos Aires University Hospital ABSTRACT Ovarian cancer usually presents with nonspecific symptoms, such as pelvic or abdominal discomfort. Abnormal uterine bleeding (AUB) is a very infrequent symptom of this neoplasm. Postmenopausal AUB can be due to steroid production by ovarian or adrenal tumors. We report the case of a postmenopausal 75-year-old patient who presented AUB. Blood tests showed high steroid lev- els (estrogens and androgens) and high CA-125 levels. Ultrasound showed a pelvic tumor, uterine myomatosis and an endometrial polyp. The patient underwent total abdominal hysterectomy with bilateral salpingo-oophorectomy. The pathological examina- tion of the surgical specimen revealed a clear cell carcinoma in the right ovary with areas of adenofibroma. The patient is being followed up by our Gynecologic Oncology Unit. KEYWORDS AUB, ovarian cancer, hyperandrogenism, hyperestrogenism. Introduction Article history Received 7 Apr 2020 – Accepted 6 Jun 2020 Abnormal uterine bleeding (AUB) occurs in approximately Contact 5% of postmenopausal women. Since 7 to 9% of AUB cases Mariana López; [email protected] are due to endometrial cancer, the primary aim of the evalu- Gynecologic Endocrinology Unit, Gynecology Division ation in all post-menopausal women with AUB is to exclude Córdoba 2351 (C1120) Buenos Aires, Argentina malignancy [1,2]. -
Pelvic Pain and Adnexal Mass: Be Aware of Accessory and Cavitated Uterine Mass
Hindawi Case Reports in Medicine Volume 2021, Article ID 6649663, 6 pages https://doi.org/10.1155/2021/6649663 Case Report Pelvic Pain and Adnexal Mass: Be Aware of Accessory and Cavitated Uterine Mass Pooya Iranpour ,1 Sara Haseli ,1,2 Pedram Keshavarz ,3 Amirreza Dehghanian ,4 and Neda Khalili 5 1Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran 2Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran 3Department of Diagnostic & Interventional Radiology of New Hospitals LTD, Tbilisi, Georgia 4Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran 5School of Medicine, Tehran University of Medical Sciences, Tehran, Iran Correspondence should be addressed to Sara Haseli; [email protected] Received 24 November 2020; Revised 19 January 2021; Accepted 30 January 2021; Published 11 February 2021 Academic Editor: Michael S. Firstenberg Copyright © 2021 Pooya Iranpour et al. +is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Accessory and cavitated uterine mass (ACUM) is a rare form of Mullerian anomaly that usually presents in young females with chronic cyclic pelvic pain and/or dysmenorrhea. +is clinical entity is often underdiagnosed as it may be mistaken for other differential diagnoses, such as pedunculated myoma or adnexal lesions. Imaging modalities, including ultrasonography and magnetic resonance imaging (MRI), accompanied with relevant and suspicious clinical findings are important tools in making acorrect diagnosis. To date, surgical excision of the mass remains the mainstay of treatment,which provides significant symptom relief. -
Actinomycosis Israeli, 129, 352, 391 Types Of, 691 Addison's Disease, Premature Ovarian Failure In, 742
Index Abattoirs, tumor surveys on animals from, 823, Abruptio placentae, etiology of, 667 828 Abscess( es) Abdomen from endometritis, 249 ectopic pregnancy in, 6 5 1 in leiomyomata, 305 endometriosis of, 405 ovarian, 352, 387, 388-391 enlargement of, from intravenous tuboovarian, 347, 349, 360, 388-390 leiomyomatosis, 309 Acantholysis, of vulva, 26 Abdominal ostium, 6 Acatalasemia, prenatal diagnosis of, 714 Abortion, 691-697 Accessory ovary, 366 actinomycosis following, 129 Acetic acid, use in cervical colposcopy, 166-167 as choriocarcinoma precursor, 708 "Acetic acid test," in colposcopy, 167 criminal, 695 N-Aceryl-a-D-glucosamidase, in prenatal diagnosis, definition of, 691 718 of ectopic pregnancy, 650-653 Acid lipase, in prenatal diagnosis, 718 endometrial biopsy for, 246-247 Acid phosphatase in endometrial epithelium, 238, endometritis following, 250-252, 254 240 fetal abnormalities in, 655 in prenatal diagnosis, 716 habitual, 694-695 Acridine orange fluorescence test, for cervical from herpesvirus infections, 128 neoplasia, 168 of hydatidiform mole, 699-700 Acrochordon, of vulva, 31 induced, 695-697 Actinomycin D from leiomyomata, 300, 737 in therapy of missed, 695, 702 choriocarcinoma, 709 tissue studies of, 789-794 dysgerminomas, 53 7 monosomy X and, 433 endodermal sinus tumors, 545 after radiation for cervical cancer, 188 Actinomycosis, 25 spontaneous, 691-694 of cervix, 129, 130 pathologic ova in, 702 of endometrium, 257 preceding choriocarcinoma, 705 of fallopian tube, 352 tissue studies of, 789-794 of ovary, 390, 391 threatened, -
The Uterus and the Endometrium Common and Unusual Pathologies
The uterus and the endometrium Common and unusual pathologies Dr Anne Marie Coady Consultant Radiologist Head of Obstetric and Gynaecological Ultrasound HEY WACH Lecture outline Normal • Unusual Pathologies • Definitions – Asherman’s – Flexion – Osseous metaplasia – Version – Post ablation syndrome • Normal appearances – Uterus • Not covering congenital uterine – Cervix malformations • Dimensions Pathologies • Uterine – Adenomyosis – Fibroids • Endometrial – Polyps – Hyperplasia – Cancer To be avoided at all costs • Do not describe every uterus with two endometrial cavities as a bicornuate uterus • Do not use “malignancy cannot be excluded” as a blanket term to describe a mass that you cannot categorize • Do not use “ectopic cannot be excluded” just because you cannot determine the site of the pregnancy 2 Endometrial cavities Lecture outline • Definitions • Unusual Pathologies – Flexion – Asherman’s – Version – Osseous metaplasia • Normal appearances – Post ablation syndrome – Uterus – Cervix • Not covering congenital uterine • Dimensions malformations • Pathologies • Uterine – Adenomyosis – Fibroids • Endometrial – Polyps – Hyperplasia – Cancer Anteflexed Definitions 2 terms are described to the orientation of the uterus in the pelvis Flexion Version Flexion is the bending of the uterus on itself and the angle that the uterus makes in the mid sagittal plane with the cervix i.e. the angle between the isthmus: cervix/lower segment and the fundus Anteflexed < 180 degrees Retroflexed > 180 degrees Retroflexed Definitions 2 terms are described -
Angiotensin II Type 1 Receptor Expression in Ovarian Cancer and Its Correlation with Tumour Angiogenesis and Patient Survival
British Journal of Cancer (2006) 94, 552 – 560 & 2006 Cancer Research UK All rights reserved 0007 – 0920/06 $30.00 www.bjcancer.com Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival K Ino1, K Shibata1, H Kajiyama1, E Yamamoto1, T Nagasaka2, A Nawa1, S Nomura1 and F Kikkawa1 1 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan; 2 Division of Pathology/Clinical Laboratory, Nagoya University Graduate School of Medicine, Nagoya, Japan Angiotensin II, a main effector peptide in the renin–angiotensin system, acts as a growth-promoting and angiogenic factor via type 1 angiotensin II receptors (AT1R). We have recently demonstrated that angiotensin II enhanced tumour cell invasion and vascular endothelial growth factor (VEGF) secretion via AT1R in ovarian cancer cell lines in vitro. The aim of the present study was to determine whether AT1R expression in ovarian cancer is correlated with clinicopathological parameters, angiogenic factors and patient survival. Immunohistochemical staining for AT1R, VEGF, CD34 and proliferating cell nuclear antigen (PCNA) were analysed in ovarian cancer tissues (n ¼ 67). Intratumour microvessel density (MVD) was analysed by counting the CD34-positive endothelial cells. Type 1 angiotensin II receptors were expressed in 85% of the cases examined, of which 55% were strongly positive. Type 1 angiotensin II receptors expression was positively correlated with VEGF expression intensity and MVD, but not with histological subtype, grade, FIGO stage or PCNA labelling index. In patients who had positive staining for AT1R, the overall survival and progression-free survival were significantly poor (P ¼ 0.041 and 0.017, respectively) as compared to those in patients who had negative staining for AT R, although VEGF, but not AT R, was an independent prognostic factor on multivariate analysis.